Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 23, 2016New England Journal of MedicineOpen Access

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJohn S. WelchWashington University in St. LouisAPAllegra A. PettiBroad InstituteCMChristopher A. MillerUniversity of Notre Dame

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Welch et al. (2016) studied this question.

synapsesocial.com/papers/69d7573ab54ccf0cfef30e87https://doi.org/10.1056/nejmoa1605949
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia2003 · 2,684 citations
  2. 2Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities2009 · 91 citations
  3. 3Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML2015 · 109 citations
  4. 4Decitabine in the treatment of acute myeloid leukemia in elderly patients2014 · 88 citations